Novo Nordisk's next-generation obesity drug, CagriSema, is regaining investor confidence after the company's stock rebounded on news that the upcoming REDEFINE 2 trial remains on track. The trial, expected to report results in Q1 2025, focuses on adults with type 2 diabetes and obesity or overweight. With CagriSema showing promise in weight loss outcomes, expectations for the second pivotal trial are high, despite the lingering controversy over the dosing protocol in REDEFINE 1.
Investor sentiment shifted after Novo Nordisk executives defended the drug’s efficacy, emphasizing that while the REDEFINE 1 results fell short of the company’s stated goal of 25% average weight loss, they still demonstrate CagriSema’s potential to compete with Eli Lilly’s Zepbound (tirzepatide). Analysts remain focused on the dosing strategy, as only 57.3% of participants in REDEFINE 1 reached the highest dose. In response, the company has announced a new Phase 3 study, REDEFINE 11, to evaluate extended treatment durations and dose re-escalation strategies aimed at optimizing weight loss outcomes.
While Novo Nordisk aims to refine its dosing protocol, legal challenges have surfaced. A securities class-action lawsuit filed in January 2025 alleges that the company misled investors by overstating confidence in achieving its 25% weight-loss target and failing to disclose before December 2024 that the REDEFINE 1 trial used a flexible dosing approach. Novo Nordisk maintains that the litigation will not materially impact its financial position.
With REDEFINE 2 results expected in Q1 2025 and regulatory submission planned for early 2026, Novo Nordisk is shifting its strategy. Novo Nordisk is now focusing on real-world patient outcomes to position CagriSema as a strong alternative to tirzepatide, rather than relying on pre-determined benchmarks. If approved, CagriSema could offer an additional option for people with type 2 diabetes who are unable to tolerate tirzepatide but still want the benefits of a dual agonist therapy. This measured approach could help ensure that future trial results are judged on their merits rather than against arbitrary expectations.
For more information, please visit:
